File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ranibizumab for myopic choroidal neovascularization

TitleRanibizumab for myopic choroidal neovascularization
Authors
KeywordsRanibizumab
choroidal neovascularization
anti-VEGF
myopia
Issue Date2020
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebt
Citation
Expert Opinion on Biological Therapy, 2020, v. 20 n. 12, p. 1385-1393 How to Cite?
AbstractIntroduction: Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic CNV. Areas covered: Review of preclinical studies and clinical trials data supporting the use of ranibizumab for myopic CNV. Discussion on the mechanisms, efficacy, safety, regulatory affairs, and future directions of ranibizumab for myopic CNV are highlighted. Expert opinion: Ranibizumab has demonstrated good efficacy and safety profile in multiple clinical trials and long-term studies for treating myopic CNV. Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently available anti-VEGF agents, ranibizumab is the only drug that is approved for the treatment of myopic CNV by the US Food and Drug Administration. In the coming few years, biosimilars of ranibizumab may become available and will have the potential to lower the cost of ranibizumab. Long-term visual gain after ranibizumab treatment for myopic CNV is limited by chorioretinal atrophy associated with pathologic myopia and further research is required to tackle the development of chorioretinal atrophy.
Persistent Identifierhttp://hdl.handle.net/10722/304547
ISSN
2020 Impact Factor: 4.388
2020 SCImago Journal Rankings: 1.088

 

DC FieldValueLanguage
dc.contributor.authorNg, DSC-
dc.contributor.authorFung, NSK-
dc.contributor.authorYip, FLT-
dc.contributor.authorLai, TYY-
dc.date.accessioned2021-09-23T09:01:36Z-
dc.date.available2021-09-23T09:01:36Z-
dc.date.issued2020-
dc.identifier.citationExpert Opinion on Biological Therapy, 2020, v. 20 n. 12, p. 1385-1393-
dc.identifier.issn1471-2598-
dc.identifier.urihttp://hdl.handle.net/10722/304547-
dc.description.abstractIntroduction: Myopic choroidal neovascularization (CNV) is one of the most vision-threatening complications in patients with pathologic myopia. Over the last decade, anti-angiogenesis therapy with anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard-of-care treatment for myopic CNV and ranibizumab has been approved for treating myopic CNV. Areas covered: Review of preclinical studies and clinical trials data supporting the use of ranibizumab for myopic CNV. Discussion on the mechanisms, efficacy, safety, regulatory affairs, and future directions of ranibizumab for myopic CNV are highlighted. Expert opinion: Ranibizumab has demonstrated good efficacy and safety profile in multiple clinical trials and long-term studies for treating myopic CNV. Cost-effective analysis has shown that ranibizumab therapy is a cost-effective treatment for myopic CNV. Among the currently available anti-VEGF agents, ranibizumab is the only drug that is approved for the treatment of myopic CNV by the US Food and Drug Administration. In the coming few years, biosimilars of ranibizumab may become available and will have the potential to lower the cost of ranibizumab. Long-term visual gain after ranibizumab treatment for myopic CNV is limited by chorioretinal atrophy associated with pathologic myopia and further research is required to tackle the development of chorioretinal atrophy.-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/ebt-
dc.relation.ispartofExpert Opinion on Biological Therapy-
dc.rightsAccepted Manuscript (AM) i.e. Postprint This is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectRanibizumab-
dc.subjectchoroidal neovascularization-
dc.subjectanti-VEGF-
dc.subjectmyopia-
dc.titleRanibizumab for myopic choroidal neovascularization-
dc.typeArticle-
dc.identifier.emailFung, NSK: nfung@hku.hk-
dc.identifier.authorityFung, NSK=rp02505-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/14712598.2021.1830969-
dc.identifier.pmid33003962-
dc.identifier.scopuseid_2-s2.0-85092462540-
dc.identifier.hkuros325497-
dc.identifier.volume20-
dc.identifier.issue12-
dc.identifier.spage1385-
dc.identifier.epage1393-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats